Health-Related Quality of Life Among Transthyretin Amyloid Cardiomyopathy Patients
ESC Heart Failure · 01.06.2023 · 10 (3) · 1871-1882
DOI: 10.1002/ehf2.14350 ↗Kurz gefasst
Fachartikel in der Zeitschrift ESC Heart Failure, online erschienen am 22.03.2023. Verfasst von Per Eldhagen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Karolinska Institute, Karolinska University Hospital, Solna, Sweden. Hauptthemen laut MEDLINE: Heart Diseases, Cardiomyopathies. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Pfizer.
Abstract (Originalsprache)
Aims
Transthyretin amyloid cardiomyopathy (ATTR CM) is a progressive and severe heart disease with physical and psychological implications. The Nordic PROACT study was conducted to investigate the health-related quality of life (HRQoL) in ATTR CM patients. Methods and results The Nordic PROACT study was a cross-sectional non-interventional study conducted in 12 cardiology hospital clinics across Norway, Sweden, Finland and Denmark. Men and women aged ≥18 years diagnosed with symptomatic ATTR CM were included. The investigator provided information on medical history, biomarkers, current treatment, co-morbidities and disease severity according to the New York Heart Association (NYHA) class and the National Amyloidosis Centre (NAC) staging. Patients completed the HRQoL questionnaires in the form of the Kansas City Cardiomyopathy Questionnaire (KCCQ), the EQ-5D-5L index with Visual Analog Scale (VAS), and the Major Depression Inventory (MDI). A total of 169 patients (mean ± SD age 77.7 ± 6.2 years) were included. Ninety-two per cent were men. Seventy-six per cent had wildtype ATTR CM (ATTRwt CM) and 15% had a hereditary form of ATTR CM (ATTRv CM) while 9% were genetically unclassified. Most patients were in NYHA class II (54%) and NAC stage 1 (53%). Participation in randomized clinical trials (RCT) was noted in 58% of the patients. The 169 ATTR CM patients had a mean ± SD KCCQ score of 64.3 ± 23.1 for total symptom score, 64.8 ± 20.9 for overall summary score (OSS) and 65.1 ± 21.5 for clinical summary score. The EQ-5D-5L total utility score was 0.8 ± 0.2 and the EQ-5D-5L VAS score was 62.9 ± 20.6. The vast majority (89%) did not report any signs of depression. Patients with ATTRv CM had a higher KCCQ OSS as compared with ATTRwt CM, while EQ-5D-5L utility score, EQ-5D-5L VAS and MDI were similar. Non-RCT participants had a poorer HRQoL as compared with RCT participants as reflected in lower KCCQ OSS and EQ-5D-5L VAS scores and a higher MDI score. Patients with higher NYHA classes and NAC disease stages had a poorer HRQoL as demonstrated by lower KCCQ and EQ-5D-5L scores and higher MDI scores. Correlation between KCCQ, EQ-5D-5L and MDI and the covariate NYHA class remained significant (P < 0.05) after adjusting for multiple testing.
Conclusions
KCCQ scores were lower than previously reported for patients with other heart diseases of non-ATTR CM origin. The HRQoL measures correlated well to NYHA class and NAC disease stage. The prevalence of depression appeared to be low.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Karolinska Institute, Karolinska University Hospital, Solna, Sweden.
- Heart and Lung Center, Helsinki University Hospital, Helsinki, Finland.
- Department of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
- Department of Cardiology, Rigshospitalet, Copenhagen, Denmark.
- Pfizer Denmark, Ballerup, Denmark.
- Pfizer Finland, Helsinki, Finland.
Förderung
- Pfizer
Zitieren
APA
Eldhagen, P., Lehtonen, J., Gude, E., Gustafsson, F., Bagger-Bahnsen, A., Vakevainen, M., Pilgaard, T., Wedell-Wedellsborg, D., Poulsen, S. H., & Nordic PROACT study group (2023). Health-Related Quality of Life Among Transthyretin Amyloid Cardiomyopathy Patients. ESC Heart Failure, 10(3), 1871-1882. https://doi.org/10.1002/ehf2.14350
Vancouver
Eldhagen P, Lehtonen J, Gude E, Gustafsson F, Bagger-Bahnsen A, Vakevainen M, et al. Health-Related Quality of Life Among Transthyretin Amyloid Cardiomyopathy Patients. ESC Heart Failure. 2023;10(3):1871-1882. doi:10.1002/ehf2.14350
BibTeX
@article{Eldhagen2023,
author = {Eldhagen, Per and Lehtonen, Jukka and Gude, Einar and Gustafsson, Finn and Bagger-Bahnsen, Anne and Vakevainen, Merja and Pilgaard, Trine and Wedell-Wedellsborg, Dorte and Poulsen, Steen Hvitfeldt and Nordic PROACT study group, Nordic PROACT study group},
title = {Health-Related Quality of Life Among Transthyretin Amyloid Cardiomyopathy Patients},
journal = {ESC Heart Failure},
year = {2023},
volume = {10},
number = {3},
pages = {1871--1882},
doi = {10.1002/ehf2.14350}
}
EUVIMED